The Princeton Neuroscience Institute’s John Hopfield has been awarded the Nobel Prize in physics for foundational discoveries and inventions that enable machine learning with artificial neural networks. He shares the prize with Geoffrey Hinton of the University of Toronto, who has been referred to as the “Godfather of… Read More
Created by DDW and sponsored by Benchling, ‘AI & ML: How technology is improving drug discovery’ is a free In Focus report available to download now. Artificial intelligence (AI) and machine learning (ML) are helping drive efficiencies across drug discovery and development processes and represent exciting tools that teams can… Read More
Novartis and Generate:Biomedicines have announced a multi-target collaboration to discover and develop protein therapeutics across multiple disease areas. The collaboration leverages Generate’s generative AI platform, ‘The Generate Platform’, to create potentially first- and best-in-class molecules through AI-based optimisation and de novo generation. The collaboration will combine The Generate Platform, which… Read More
Insilico Medicine has shared positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055, a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase). The drug was designed utilising generative AI to treat idiopathic pulmonary fibrosis (IPF). The study met both its primary… Read More
Dr Mutlu Dogruel, Vice President of AI Solutions at Cresset, examines AI’s transformative potential, highlights the current challenges and introduces a series of potential solutions to implement AI in the drug discovery landscape successfully. The use of artificial intelligence (AI) is creating a paradigm shift in drug discovery and optimisation… Read More
This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI is critical to solving new complexities in drug discovery and… Read More
Mirit Eldor, Managing Director, Life Sciences Solutions, Elsevier, looks at how artificial intelligence (AI) can improve the hit-to-lead process for small molecules. Early drug discovery takes an average of three-to-six years and accounts for 42% of total costs1 in the development of a new drug. It’s therefore no surprise that… Read More
OpenFold, a non-profit artificial intelligence (AI) research consortium focused on developing free and open-source software tools for biology and drug discovery, has added six new industry members. Joining the consortium are Astex Pharmaceuticals, Biogen, Congruence Therapeutics, Polaris Quantum Biotech, Psivant Therapeutics, and SandboxAQ. “This… Read More
The Memorial Sloan Kettering Cancer Center (MSK) will be collaborating with Absci Corporation to discover and develop novel cancer therapeutics using generative artificial intelligence (AI) for up to six programmes. Under the terms of the collaboration, Absci and MSK’s cancer research teams will co-develop therapeutics using… Read More
Biotechnology company Rejuvenate Biomed has announced a partnership with analytics company SAS to develop a drug repurposing discovery tool to help researchers and scientists uncover medically relevant insights about drugs, diseases, and biological networks. The tool will be developed using SAS’ artificial intelligence (AI) and data platform, Viya. It will… Read More
Collaborators SandboxAQ and NVIDIA have reported a breakthrough that allows an 80-fold speed increase in computational chemistry calculations. SandboxAQ leverages Large Quantitative Models (LQMs) and the NVIDIA CUDA-accelerated Density Matrix Renormalization Group (DMRG) algorithm. Combining the CUDA-DMRG algorithm, the NVIDIA Quantum platform, and NVIDIA… Read More
Abiologics, a Flagship Pioneering company, has launched to develop a new class of supranatural and programmable medicines called Synteins. Synteins are computationally-generated and synthesised with novel building blocks, potentially providing treatments across a wide range of diseases. Flagship has initially committed $50 million to advance the company’s platform and develop… Read More
DDW Editor Reece Armstrong takes a look at some recent advances in screening that are helping scientists in the drug discovery process. Screening is an essential part of the drug discovery process in which researchers analyse large libraries of compounds in order to discover promising molecule that demonstrate a therapeutic… Read More
Briefly Bio, a software company that hopes to make lab work more reproducible by helping scientists capture and share their work, has launched with a $1.2m pre-seed funding round. The financing was led by Compound VC, with participation from NP Hard, Tiny VC and angel investors across tech and biotech. Read More
In vivo testing has validated Oxford Drug Design’s potential first-in-class approach against multiple tumours, designed using its AI platform. The results of a 28-day mouse trial showed clear efficacy as well as dose response. The company’s approach is based on a novel target, leucyl-tRNA… Read More
There is limitless scope for generative AI to transform regulatory processes. But where to start? ArisGlobal’s Agnes Cwienczek and Renato Rjavec describe use cases where AI is already delivering tangible everyday benefits. As life sciences companies’ investments in regulatory data capture, enrichment and exchange continue to rise in line with… Read More
